EMA agrees on ''black triangle'' for new drugs launched in EU
This article was originally published in Scrip
All new products launched in the EU will have to display a black inverted triangle on their product information denoting that the product is subject to additional monitoring, if the European Commission accepts the advice of the new pharmacovigilance committee (PRAC) at the European Medicines Agency.
You may also be interested in...
The bedding-in period is ending for Europe’s one-year-old system for preventing the circulation of fake medicines, and the scheme is gearing up for a more fully operational stage.
EU and US regulators have opposing views when it comes to Merck's applications for a new indication and new dosing schedule for the company's successful PD-1 inhibitor Keytruda.
Regulators have pulled out all the stops in their efforts to get the Ebola vaccine to the marketing authorization stage in Africa.